These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3800686)

  • 1. [Treatment of myasthenia gravis by immunosuppressive non-steroidal drugs].
    De Assis JL; Marchiori PE; Scaff M; Zambon AA
    Arq Neuropsiquiatr; 1986 Jun; 44(2):109-16. PubMed ID: 3800686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppressive drug therapy in myasthenia gravis.
    Niakan E; Harati Y; Rolak LA
    Arch Neurol; 1986 Feb; 43(2):155-6. PubMed ID: 3947257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of myasthenia gravis with plasmapheresis (author's transl)].
    Reuther P; Wiebecke D; Hertel G; Böske A; Mertens HG
    Dtsch Med Wochenschr; 1979 Dec; 104(51):1806-10. PubMed ID: 520174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosuppressive treatment for juvenile myasthenia gravis.
    Badurska B; Ryniewicz B; Strugalska H
    Eur J Pediatr; 1992 Mar; 151(3):215-7. PubMed ID: 1601015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to plasmapheresis and immunosuppressive drug therapy in sixty myasthenia gravis patients.
    Dau PC
    Ann N Y Acad Sci; 1981; 377():700-8. PubMed ID: 6951494
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical characteristics and prognosis of myasthenia gravis in older people.
    Evoli A; Batocchi AP; Minisci C; Di Schino C; Tonali P
    J Am Geriatr Soc; 2000 Nov; 48(11):1442-8. PubMed ID: 11083321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis.
    Dau PC; Lindstrom JM; Cassel CK; Denys EH; Shev EE; Spitler LE
    N Engl J Med; 1977 Nov; 297(21):1134-40. PubMed ID: 917042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis.
    Bromberg MB; Wald JJ; Forshew DA; Feldman EL; Albers JW
    J Neurol Sci; 1997 Sep; 150(1):59-62. PubMed ID: 9260858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies.
    Lin PT; Martin BA; Weinacker AB; So YT
    Muscle Nerve; 2006 Mar; 33(3):433-5. PubMed ID: 16116645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stable remissions in myasthenia gravis.
    Perez MC; Buot WL; Mercado-Danguilan C; Bagabaldo ZG; Renales LD
    Neurology; 1981 Jan; 31(1):32-7. PubMed ID: 7192824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azathioprine in the treatment of myasthenia gravis.
    Witte AS; Cornblath DR; Parry GJ; Lisak RP; Schatz NJ
    Ann Neurol; 1984 Jun; 15(6):602-5. PubMed ID: 6742794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasmapheresis as a guide for azathioprine therapy in prednisone-resistant myasthenia gravis.
    Rodnitzky RL; Bosch EP
    Muscle Nerve; 1981; 4(6):529-30. PubMed ID: 7311992
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris.
    Olszewska M; Kolacinska-Strasz Z; Sulej J; Labecka H; Cwikla J; Natorska U; Blaszczyk M
    Am J Clin Dermatol; 2007; 8(2):85-92. PubMed ID: 17428113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasmapheresis in myasthenia gravis.
    Dau PC
    Prog Clin Biol Res; 1982; 88():265-85. PubMed ID: 7100216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azathioprine as a single immunosuppressive drug in the treatment of myasthenia gravis.
    Cosi V; Lombardi M; Erbetta A; Piccolo G
    Acta Neurol (Napoli); 1993 Apr; 15(2):123-31. PubMed ID: 8328322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma exchange combined with cytotoxic drugs and lymphocytapheresis for myasthenia gravis.
    Valbonesi M; Garelli S; Zerbi D; Forlani G; Cornelio F; Pelucchetti D
    Vox Sang; 1982; 43(3):142-6. PubMed ID: 7147857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasmapheresis: a new treatment modality for the patient with severe myasthenia gravis.
    Eppel M; Streib EW
    Nebr Med J; 1982 Apr; 67(4):72-4. PubMed ID: 7088214
    [No Abstract]   [Full Text] [Related]  

  • 18. Factors influencing the relapse risk at steroid dose reduction in myasthenia gravis.
    Scherpbier HJ; Oosterhuis HJ
    Clin Neurol Neurosurg; 1987; 89(3):145-50. PubMed ID: 3665287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunosuppressive agents for myasthenia gravis.
    Hart IK; Sathasivam S; Sharshar T
    Cochrane Database Syst Rev; 2007 Oct; (4):CD005224. PubMed ID: 17943844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ocular myasthenia].
    Huber A
    Klin Monbl Augenheilkd; 1985 Mar; 186(3):158-60. PubMed ID: 3999598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.